Invitrogen™ Ebronucimab Recombinant Monoclonal Antibody

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Ebronucimab, also known as AK102, is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of cholesterol homeostasis. The PCSK9 gene, located on chromosome 1p32.3, encodes the proprotein convertase subtilisin/kexin type 9 (PCSK9), which is a 692-amino acid protein pivotal in cholesterol metabolism. Structurally, PCSK9 comprises a signal peptide, a pro-domain, a catalytic domain, and a cysteine-histidine rich C-terminal domain. The signal peptide is cleaved in the endoplasmic reticulum, allowing the mature protein to be secreted. Functionally, PCSK9 binds to low-density lipoprotein receptors (LDLR) on the surface of hepatocytes, leading to their degradation and hence increased levels of circulating LDL cholesterol. Variants of PCSK9 can significantly influence an individual's cholesterol levels and cardiovascular risk. Therapies targeting PCSK9, such as monoclonal antibodies, are effective in lowering LDL cholesterol, providing significant cardiovascular benefits.